TTOO(Delisted)
T2 Biosystems·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 1
Low Cash Short-term Debt Ratio
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TTOO
T2 Biosystems, Inc.
A leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes
101 Hartwell Avenue, Lexington, Massachusetts 02421
--
T2 Biosystems, Inc., was established on April 27, 2006. The company is an in vitro diagnostic company and a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. The company's technology enables rapid detection of pathogens, biomarkers and abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets within detection limits as low as one colony-forming unit per milliliter, or CFU/mL. The company is currently targeting a range of healthcare diseases that are considered severely underserved, with an initial focus on those diseases where rapid detection may enable faster targeted antimicrobial therapy, improve patient outcomes and reduce costs.
Company Financials
EPS
TTOO has released its 2024 Q3 earnings. EPS was reported at -0.57, versus the expected -0.75, beating expectations. The chart below visualizes how TTOO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TTOO has released its 2024 Q3 earnings report, with revenue of 1.99M, reflecting a YoY change of 34.85%, and net profit of -10.12M, showing a YoY change of 34.41%. The Sankey diagram below clearly presents TTOO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
